Polyclonal Antibody to Amyloid Beta Precursor Protein Binding Protein 1 (APPBP1)
| Code | Size | Price |
|---|
| PAC219Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAC219Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAC219Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAC219Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
NAE1; HPP1; Ula-1; NEDD8-Activating Enzyme E1 Regulatory Subunit 1; Amyloid protein-binding protein 1; Proto-oncogene protein 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Amyloid Beta Precursor Protein Binding Protein 1
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:160-640<br/>Immunohistochemistry: 5-20ug/mL;1:16-64<br/>Immunocytochemistry: 5-20ug/mL;1:16-64<br/>Optimal working dilutions must be determined by end user.
References
https://pubmed.ncbi.nlm.nih.gov/32839427/;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Amyloid Beta Precursor Protein Binding Protein 1 (APPBP1) | RPC219Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||